References



 
1. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Rowan Kuiper, Mark van Duin, Martin van Vliet, Annemiek Broijl, Bronno van der Holt, Laila el Jarari, Erik van Beers, George Mulligan, Hervé Avet-Loiseau, Walter Gregory, Gareth J Morgan, Hartmut Goldschmidt, Henk M Lokhorst, and Pieter Sonneveld.. Blood. 2015 Sep 1. pii: blood-2015-05-644039.[no link]
 
2. SKY92 GEP, iFISH and ISS comparisons for risk stratification in multiple myeloma. EHA 2015 Annual Meeting Abstract P661. [link]
 
3. Proteasome Inhibitor Treatment Response can be Predicted by Gene Expression Profiling in Multiple Myeloma. EHA 2014 Annual Meeting Abstract  S1286. [link]
 
4. Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System.  ASH 2014 Annual Meeting Abstract 3358. [link]
 
5. Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients. ASH 2014 Annual Meeting Abstract 2141. [link]
 
6. Single Sample Application of the EMC92/SKY92 Signature Using the MMprofiler.  ASH 2014 Annual Meeting Abstract 2026. [link]
 
7. High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). ASH 2013 Annual Meeting Abstract 1854. [link]
 
8. Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM). ASH 2013 annual meeting Abstract 3220.  [link]
 
9. Comparison of multiple myeloma prognostic markers: combined GEP and ISS discerns three robust risk categories. ASH 2011 [link]
 
10. Combining FISH and GEP Signatures In Multiple Myeloma; Towards A More Robust And Meaningful High Risk Definition. Martin Van Vliet, Rowan Kuiper, Annemiek Broijl, Yvonne de Knegt, William Hoos, Leonie de Best, Gareth Morgan, Walter Gregory, Mark van Duin, Erik Van Beers, Pieter Sonneveld. EHA 2013 Annual Meeting Abstract S580. [link]
 
11. An assay for simultaneous diagnosis of t(4;14),t(11;14), t(14;16)/t(14;20), del1p, add1q, del13q, del17p, MS/MF expression clusters, and the SKY-92 high risk signature in multiple myeloma patients. Martin van Vliet, R Kuiper, A Broijl, Y de Knegt, W Hoos, L de Best, M van Duin, E Van Beers, P Sonneveld. EHA 2013 Annual Meeting Abstract P234. [link]
 
12. A high risk survival signature for multiple myeloma. Rowan Kuiper, A Broyl, Y de Knegt, M van Vliet, E van Beers, B van der Holt, L el Jarari, G Mulligan, W Gregory, G Morgan, H Goldschmidt, H Lokhorst, M van Duin, P Sonneveld. EHA 2012 Annual Meeting Abstract 0552. [link]
 
13. A gene expression signature for high-risk multiple myeloma. Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P. Leukemia. 2012 Nov;26(11):2406-13. [no link]
 
14. A High-Risk Survival Classifier for Multiple Myeloma. Rowan Kuiper, Annemiek Broyl, Yvonne de Knegt, Martin H. van Vliet, Erik H. van Beers, Bronno van der Holt, Laila el Jarari, George Mulligan, Gareth Morgan, Walter M Gregory, Hartmut Goldschmidt, Henk M. Lokhorst, Mark van Duin, and Pieter Sonneveld, ASH 2011 annual meeting Abstract 1800. [link]
 
15. Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial. Annemiek Broyl, Rowan Kuiper, Martin H. van Vliet, Erik H. van Beers, Yvonne de Knegt, Bronno van der Holt, Laila el Jarari, Berna Beverloo, H. Lokhorst, Sonja Zweegman, George Mulligan, Hartmut Goldschmidt, Mark van Duin, and Pieter Sonneveld. ASH 2011 annual meeting Abstract 445. [no link]